用免疫检查点抑制剂治疗原发性肺癌合并肺泡蛋白沉着症病例报告

IF 0.8 Q4 RESPIRATORY SYSTEM

Respiratory Medicine Case Reports Pub Date : 2024-01-01 DOI:10.1016/j.rmcr.2023.101976

Mika Horie, Kazuhisa Nakashima, Yoshihiro Amano, Yohei Shiratsuki, Kotaro Murakami, Takeshi Isobe, Yukari Tsubata

{"title":"用免疫检查点抑制剂治疗原发性肺癌合并肺泡蛋白沉着症病例报告","authors":"Mika Horie, Kazuhisa Nakashima, Yoshihiro Amano, Yohei Shiratsuki, Kotaro Murakami, Takeshi Isobe, Yukari Tsubata","doi":"10.1016/j.rmcr.2023.101976","DOIUrl":null,"url":null,"abstract":"<div><p>Primary lung cancer with pulmonary alveolar proteinosis (PAP) is a rare condition. We present a case of a patient with primary lung cancer with PAP treated with an immune checkpoint inhibitor (ICI). A 62-year-old man was diagnosed with autoimmune PAP 8 years prior to current admission. Lung adenocarcinoma was found in his right lung, and platinum-based chemotherapy was administered, followed by atezolizumab. He experienced disease progression after atezolizumab treatment, whereas ICI-induced pneumonia or exacerbation of PAP did not occur. This indicates that ICI may be safely used in patients with primary lung cancer with PAP.</p></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"47 ","pages":"Article 101976"},"PeriodicalIF":0.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213007123001715/pdfft?md5=fbae966b916333d0b9a1abaca78001c9&pid=1-s2.0-S2213007123001715-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Primary lung cancer with pulmonary alveolar proteinosis treated with immune checkpoint inhibitor: A case report\",\"authors\":\"Mika Horie, Kazuhisa Nakashima, Yoshihiro Amano, Yohei Shiratsuki, Kotaro Murakami, Takeshi Isobe, Yukari Tsubata\",\"doi\":\"10.1016/j.rmcr.2023.101976\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Primary lung cancer with pulmonary alveolar proteinosis (PAP) is a rare condition. We present a case of a patient with primary lung cancer with PAP treated with an immune checkpoint inhibitor (ICI). A 62-year-old man was diagnosed with autoimmune PAP 8 years prior to current admission. Lung adenocarcinoma was found in his right lung, and platinum-based chemotherapy was administered, followed by atezolizumab. He experienced disease progression after atezolizumab treatment, whereas ICI-induced pneumonia or exacerbation of PAP did not occur. This indicates that ICI may be safely used in patients with primary lung cancer with PAP.</p></div>\",\"PeriodicalId\":51565,\"journal\":{\"name\":\"Respiratory Medicine Case Reports\",\"volume\":\"47 \",\"pages\":\"Article 101976\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2213007123001715/pdfft?md5=fbae966b916333d0b9a1abaca78001c9&pid=1-s2.0-S2213007123001715-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respiratory Medicine Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213007123001715\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory Medicine Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213007123001715","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

摘要

原发性肺癌合并肺泡蛋白增生症（PAP）是一种罕见病。我们介绍了一例使用免疫检查点抑制剂（ICI）治疗原发性肺癌合并肺泡蛋白沉着症的患者。一名 62 岁的男性患者在入院 8 年前被诊断出患有自身免疫性肺泡蛋白增生症。他的右肺发现了肺腺癌，接受了铂类化疗，随后又接受了阿特珠单抗治疗。阿特珠单抗治疗后，他的病情出现进展，而 ICI 引发的肺炎或 PAP 恶化并未发生。这表明，ICI 可以安全地用于伴有 PAP 的原发性肺癌患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Primary lung cancer with pulmonary alveolar proteinosis treated with immune checkpoint inhibitor: A case report

Primary lung cancer with pulmonary alveolar proteinosis (PAP) is a rare condition. We present a case of a patient with primary lung cancer with PAP treated with an immune checkpoint inhibitor (ICI). A 62-year-old man was diagnosed with autoimmune PAP 8 years prior to current admission. Lung adenocarcinoma was found in his right lung, and platinum-based chemotherapy was administered, followed by atezolizumab. He experienced disease progression after atezolizumab treatment, whereas ICI-induced pneumonia or exacerbation of PAP did not occur. This indicates that ICI may be safely used in patients with primary lung cancer with PAP.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊